FierceBiotechOriginal article
{"a":[{"_":"Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug","$":{"href":"/pharma/scholar-rock-ditches-novo-legacy-catalent-plant-fda-refiling-sma-drug","hreflang":"en"}}]}
NDA FilingapitegromabNegative
AI Analysis
Summary
Scholar Rock is refiling its FDA application for apitegromab, a spinal muscular atrophy drug, after dropping Novo Nordisk's Catalent manufacturing facility due to an unfavorable FDA inspection result classified as 'Official Action Indicated.'
Outcome Details
Scholar Rock refiling FDA application after dropping Catalent facility due to 'Official Action Indicated' inspection classification
Importance:6/10
Sentiment:
-0.60
FDA refilingmanufacturing changeSMAcontract manufacturerregulatory setback
Read the original article
Published by FierceBiotech on August 10, 2026 10:09 AM